ADMS
Adamas Pharmaceuticals Inc
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 118.22M; Volume: 97.24K; AvgVol 3m: 512.64K; Beta: 2.30;
Cost estimate:
P/E: –; EPS: -2.79; EPS growth quarter/prev quarter: 58.40%;
EPS growth this year: 22.00%; EPS growth past 5 years: -52.90%;
EPS ttm: -2.79;
P/S: 1.94; P/B: ; P/Cashflow: 1.20; P/FCF: ;
Sales: 63.55M; Sales growth quarter/prev quarter: 48.00%; Sales growth past 5 years: -0.40%;
Profitability:
Gross Margin: 96.30%; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -50.20%; ROE – return on equity: ; LT Debt/Equity: ; Total Debt/Equity: ;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 0.60%; Insider Transactions:0.00%;
Institutional Ownership: 68.10%; Institutional Transactions: -10.47%;
Data update: 07.10.2020.